Eli Lilly and Company and Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, collaborate to research new medicines under development to fight cancer.
As per the agreement, Dana-Farber researchers and Lilly scientists will work collaboratively on preclinical and clinical studies, molecular studies of patient samples and the design and conduct of clinical trials, which may result in important advances in the science of cancer care. The agreement also allows Dana-Farber scientists to conduct independent studies on select Lilly compounds. Following research conducted at Dana-Farber, the evaluated compounds will still be fully owned by Lilly. Financial terms of the agreement are not being disclosed.
Subscribe to PharmaTutor News Alerts by Email >>
